论文部分内容阅读
目的:研究依折麦布辛伐他汀片与不同剂量的辛伐他汀片用于PCI患者二级预防中的疗效和安全性。方法:入选448例在我院行经皮冠状动脉介入治疗(PCI)的患者,随机分为A组(148例),给予依折麦布辛伐他汀片(10mg/20mg);B组(150例),给予辛伐他汀片40mg;C组(150例),给予辛伐他汀片20mg。所有患者均每晚睡前服药1次。对出院患者进行定期随访,评估其降脂疗效、安全性和主要不良心血管事件(MACE)发生率。结果:1A组和B组患者的血脂达标率和低密度脂蛋白胆固醇(LDL-C)降幅显著高于C组患者(P<0.05),A组患者发生肝功能异常的比率显著低于B组患者。2患者PCI术后血脂不达标、血压控制不达标、血糖控制不达标、未服用依折麦布辛伐他汀片与主要不良心血管事件发生独立相关。结论:依折麦布辛伐他汀片用于PCI患者的二级预防能显著降低血脂,安全性高,减少MACE发生率。
Objective: To study the efficacy and safety of ezetimibe and statin tablets in the secondary prevention of PCI. Methods: A total of 448 patients undergoing percutaneous coronary intervention (PCI) in our hospital were enrolled. Patients were randomly divided into group A (148 cases) and ezetimibe (10 mg / 20 mg) ), Simvastatin tablets 40mg; C group (150 cases), given simvastatin tablets 20mg. All patients take medicine once a night before going to bed. Discharged patients were regularly followed up to assess their lipid-lowering efficacy, safety and incidence of major adverse cardiovascular events (MACE). Results: The blood lipid compliance rate and the LDL-C decrease in group 1A and group B were significantly higher than those in group C (P <0.05). The rate of liver dysfunction in group A was significantly lower than that in group B patient. 2 patients after PCI non-compliance of blood lipids, blood pressure control is not compliance, blood glucose control does not meet the standard, did not take ebetizer simvastatin tablets and major adverse cardiovascular events independently. Conclusion: Secondary prevention with ezetimibe and statin tablet in patients with PCI can significantly reduce blood lipid levels, with high safety and reduce the incidence of MACE.